FOLH1 and posterior cortical atrophy: As an emerging imaging modality, prostate surface membrane antigen (PSMA) positron emission tomography-computed tomography (PET/CT) has been approved by the United States Food and Drug Administration (FDA) and is recommended for detecting metastases and restaging PCa in cases of biochemical recurrence (BCR) [2].